Document:

EXHIBIT 10.54

                                    EXHIBIT D

                          REGISTRATION RIGHTS AGREEMENT

THIS  REGISTRATION  RIGHTS  AGREEMENT  (the "Agreement"), dated as of August 11,
                                             ---------
2003, by and between New York Health Care, Inc., a New York corporation with its
principal  offices in Brooklyn, NY (the "Company"), and NexGen Bacterium, Inc. a
                                         -------
Panamanian  corporation  with  its  registered  offices  in  Panama City, Panama
("NEXGEN").

The  parties  hereto,  for  good  and  valuable  consideration,  the receipt and
sufficiency of which are hereby acknowledged, and intending to be legally bound,
hereby  agree  as  follows:

1.   DEFINITIONS.  The  following  terms  have  the  following  meanings:

(a)  "Act"  means the U.S. Securities Act of 1933, as amended, and the rules and
      ---
     regulations  promulgated  thereunder.

(b)  "Commission"  means  the  Securities  and  Exchange  Commission.
      ----------

(c)  "Common  Stock"  means  the Common Stock, par value $0.01 per share, of the
      -------------
     Company.

(d)  "Registrable  Securities"  means  any  Shares  (as  defined herein), of the
      -----------------------
     Company  owned  by  NEXGEN.

(e)  "Registration,"  "register"  and like words mean compliance with all of the
      -------------    --------
     laws,  ules  and  regulations (federal, state and local), and provisions of
     agreements  and  corporate  documents  pertaining to the public offering of
     securities,  including registration of any public offering of securities on
     any  form  under  the  Act.

(f)  "Shares" means any shares of the $.01 par valve common stock of the Company
      ------
     received  by  NEXGEN  in connection with the August 11, 2003 Asset Purchase
     Agreement  among  The  Bio  Balance  Corp.,  the  Company  and  NEXGEN.

     2.     (a)  PIGGYBACK  REGISTRATION.  At any time following the date hereof
and  prior  to  the  Registration of all of the Shares, and subject to the other
provisions  of this Agreement, the Company shall advise NEXGEN by written notice
at  least  ten (10) days prior to the filing of any registration statement under
the  Act  by  the Company (other than a registration statement on Form S-4, Form
S-8  or subsequent similar forms), and will upon the provision of written notice
from  NEXGEN  as described below include in any such registration statement such
information  as  may  be required to permit a public offering of the Registrable
Securities  desired  to be registered by  NEXGEN.  If NEXGEN desires to have its
Registrable  Securities  included  in  such  registration  statement, it must so
advise  the Company in writing within ten (10) days after the date of receipt of
the  Company's  notice  of registration, setting forth the amount of Registrable
Securities  for  which registration is requested; provided, however, that if the
sole  underwriter  or

<PAGE>
managing  underwriters  advise the Company that the inclusion in the offering of
securities  proposed  to be sold by NEXGEN would adversely affect the ability of
the  Company  to complete the offering, then the Company shall have the right to
reduce  the  number  of shares for which NEXGEN is seeking registration on a pro
rata  basis with all other selling shareholders seeking registration in any such
registration  statement. NYHC shall use its best efforts to cause such Statement
to  be  filed  and to become effective, and, for a period of six (6) consecutive
months  from the date such Statement is declared effective by the Commission and
to  keep  current  the Prospectus included in such Statement, either through the
filing  of  periodic reports under the Exchange Act, or by filing post-effective
amendments  to  the  Statement,  so  as to permit the public sale of the Shares.
NEXGEN  acknowledges,  however, that prior to executing any sales of the Shares,
it  will  confirm with the Company that the Prospectus included in the Statement
is  up-to-date  and  that  such  Shares  may  be  lawfully  sold.

     (b)     DEMAND  REGISTRATION  RIGHTS.  In  the  event  that  the Shares are
excluded  from  registration  as  described  in  2(a)  above  (the  "initial
registration"),  the  Company  will  at  its  own  expense  file  a registration
statement at the next earliest practicable date not later than 90 days following
completion  of that offering and include the Shares (the "Demand Registration").
Such  registration  statement  may  be  a post effective amendment, registration
under  Form S-3 or any other registration process available to it under the then
existing  Commission  guidelines.  In  the  event the Demand Registration is not
filed  by  the 90th day following the completion of the offering included in the
initial  registration,  the Company agrees that it will then be in default under
the terms of this Agreement.  The holder of the Shares shall have all rights and
remedies  available  to  him  to  seek  damages  as  well  as  to  seek specific
performance.

     3.     INFORMATION  TO  BE FURNISHED BY NEXGEN. NEXGEN shall furnish to the
Company  in  writing all information within its possession or knowledge required
by  the applicable rules and regulations of the Commission and by any applicable
state securities or blue sky laws concerning NEXGEN, the proposed method of sale
or  other disposition of the shares of Common Stock being sold by NEXGEN in such
offering,  and  the  identity  of  and  compensation  to be paid to any proposed
underwriter  or  underwriters  to  be employed in connection with such offering.

     4.     COSTS AND EXPENSES.  The Company shall pay all costs and expenses in
connection  with  the Registration under this Agreement; provided, however, that
                                                         --------  -------
NEXGEN  and  the  holder shall bear the fees and expenses of its own counsel and
accountants  and  any selling expenses relating to Registrable Shares registered
on  behalf  of  NEXGEN or the holder in connection with such offering, including
without  limitation,  any transfer taxes, underwriting discounts or commissions.

     5.     NOTICES.  All  notices  and  other  communications  provided  for
hereunder  must be in writing and shall be deemed to have been given on the same
day  when personally delivered or sent by confirmed facsimile transmission or on
the  next  business  day  when  delivered by receipted courier service or on the
third  business  day when mailed with sufficient postage, certified mail, return
receipt requested, to the following addresses: (a) if to the Company, to The Bio
Balance  Corp.,  16  East 34th Street, New York, NY 10016, Attention Paul Stark,
President,  and to New York Health Care, Inc., 1850 McDonald Avenue Brooklyn New
York  11223,  Attention:

<PAGE>
Jerry  Braun,  President;  and  (b) if to NEXGEN, to (insert contact information
here) President, or to such other address as it may be changed from time to time
on  the  books  of  the  Company by written notice. Copies of all notices to the
Company  shall  be  simultaneously  given  to William J. Davis, Esq., Scheichet&
Davis,  P.C.,  800  Third  Avenue  -  29th  Floor, New York, NY 10022, fax (212)
371-7634,  e-mail william@scheichetdavis.com. Each party hereto may from time to
time  change  the  address  to which notices to it are to be delivered or mailed
hereunder  by  notice  in  writing  to  the  other  party.

     6.     ENTIRE  AGREEMENT;  MODIFICATION  OF  AGREEMENT;  CONSENTS.  This
Agreement  constitutes  the  entire  agreement  between  the parties hereto with
respect to the subject matter hereof.  Changes in or additions to this Agreement
may  be  made  and/or compliance with any covenant or condition herein set forth
may  be  omitted  only  upon  written  consent  of  all  the  parties  hereto.
     7.     SUCCESSORS  AND  ASSIGNS.  This  Agreement shall be binding upon and
inure  to  the  benefit  of  the  parties  hereto and their respective permitted
successors,  transferees  and  assigns.

     8.     GOVERNING  LAW.  This  Agreement  shall be governed by and construed
and enforced in accordance with the laws of the State of New York without giving
effect  to  the choice of law or conflict of laws principles. The New York state
and federal courts in New York shall have jurisdiction over any and all disputes
arising  out  of  or  relating  to  this  Agreement.

     9.     COUNTERPARTS.  This  Agreement may be executed in counterparts, each
of which shall be deemed an original and both of which together shall constitute
one  and  the  same  agreement.

     IN WITNESS WHEREOF, the parties hereto have caused this Registration Rights
     Agreement  to  be  duly  executed  as  of  the  date first set forth above.

                                NEW  YORK  HEALTH  CARE,  INC.

                                By:  /s/  Jerry  Braun
                                   -------------------
                                Name:  Jerry  Braun
                                     --------------
                                Its:  President,  August  20,  2003
                                    -------------------------------

                                NEXGEN  BACTERIUM,  INC.

                                By:  /s/  Michel  Marechel     Norma  Nuezo
                                   ----------------------------------------
                                Name:  Michel  Marechal  Norma  Nuezo
                                       ------------------------------
                                Its:  General  Attorneys
                                      ------------------

<PAGE>EXHIBIT 10.55

LICENSE  AGREEMENT
BIO  BALANCE  CORP.  -  NEXGEN  BACTERIUM  INC.
As  of  August  11,  2003

This  License  is  entered  into,  as  of August 11, 2003 (the "Effective Date")
between  Bio  Balance  Corp.  a  Delaware  corporation  ("Licensor"), and NexGen
Bacterium  Inc.,  a  Panamanian  corporation  ("Licensee").

          RECITALS

Contemporaneously  with  the execution of this Agreement, Licensor  entered into
an  agreement  ("Asset  Purchase  Agreement")  with Licensee for the purchase of
certain  assets  ("Assets"  or  "Technology") as described in the Asset Purchase
Agreement  and  Exhibit  A  thereto  appended.

Licensor  has  filed,  in respect of the Assets, a patent application, a copy of
which  is  hereto  appended  (the  "Patent  Application").

NOW  THEREFORE,  the  parties  agree  as  follows:

1.      DEFINITIONS     For  purposes  of  this  Agreement,  the following terms
shall  have  the  meanings  set  forth  below:

"LICENSED  PATENTS"  shall  mean  (i)  the  Patent  Application and all  patents
issuing  therefrom;  (ii)  any  international  counterparts  thereof;  (iii) any
divisionals,  continuations,  continuations-in-part  (except as provided below),
refilings,  and  extensions  of  any  of  the  foregoing  patents  and  patent
applications;  (iv)  all  substitutions,  reissues,  renewals,  reexaminations,
patents  of  addition,  and  inventors'  certificates  thereof,  patent  term
extensions,  supplementary protection certificates and exclusivity extensions of
the  foregoing  patents;  and (v) all patents issuing from any of the foregoing.
"Licensed  Patents" shall also include patents and/or patent applications  filed
or  issuing after the Effective Date to the extent of any claims relating to the
Licensed  Technology.

"LICENSED  TECHNOLOGY"  shall  mean  all  tangible or intangible know-how, trade
secrets,  inventions (whether or not patentable), data, clinical and preclinical
results,  analytical reference materials and all confidential and/or proprietary
chemical  substances,  biological  materials,  assays, and technical information
(collectively, "Technology") developed prior to the Effective Date in connection
with  novel  probiotic  bacterial  strains  of Bacillus subtilis HE and Bacillus
licheniformis,  including,  in  particular,  ATCC deposited strains PTA-5310 and
PTA-5311,  pharmaceutical  compositions, foodstuff and feedstuff containing same
and  use  thereof  in  the treatment of diseases and disorders which may benefit
from  probiotic  treatment  as  well  as use thereof as pharmaceutical carriers.

"PRODUCTS"  shall  mean  finished  or  semi-finished  goods,  the  development,
manufacture  or use of which relies upon or derives from the Licensed Technology
and  which would otherwise infringe the Licensed Patents, exclusive of any goods
developed,  manufactured,  sold  or  commonly  used  as  a  treatment  for
gastro-intestinal  diseases  or  disorders.

2.      LICENSE.

<PAGE>
2.1     GRANT.   For good and valuable consideration the sufficiency and receipt
of  which  are  hereby  acknowledged  by Licensor, Licensor grants to Licensee a
worldwide,  paid  up,  exclusive,  perpetual, royalty free, non-transferable and
non-assignable  license  to  use the Licensed Patents and Licensed Technology in
order  to  make,  have  made, use, sell, offer for sale, and import the Products
(collectively,  the  "Uses")  and  for  no  other  use  or  purpose.

2.2     CONDITIONS  AND LIMITATIONS   The grant of the aforementioned License by
Licensor  to  Licensee  is  subject to the following conditions and limitations:

2.2.1     The  Licensed  Patents  and  License  Technology,  inclusive  of  any
developments,  improvements,  extensions,  new  applications,  upgrades  and
modifications  thereof,  are  proprietary to Licensor, and Licensor shall retain
all  rights,  title  and  interest  therein.

2.2.2     Licensee  shall  have  no  right to sub-license its rights pursuant to
this  Agreement.

2.2.3     The  terms  of  Section  9.3  (iii)  of  the  Asset Purchase Agreement
notwithstanding, but subject to the terms of Section 2.2.1 above, Licensee shall
be  entitled  to  engage in research and development of the Licensed Patents and
Licensed  Technology,  provided,  however,  that  such  research  or development
relates  directly  to  the  Uses.

3.     DELIVERY.  Licensor  shall,  deliver  to  Licensee  copies  of the Patent
prosecution  history file for the Patent Application, and of all pending and all
final  issued  patents  and  patent  claims  contained  therein.

4.     REPRESENTATIONS  AND  WARRANTIES

4.1  CORPORATE  EXISTENCE  AND  POWER.  As  of  the  Effective  Date, each Party
represents  and  warrants  to  the  other  that  it  (a)  is  a corporation duly
organized,  validly existing and in good standing under the laws of the state in
which  it  is  incorporated, and {b}  has full corporate power and authority and
the  legal  right to own and operate its property and assets and to carry on its
business  as  it  is  now being conducted and is contemplated in this Agreement,
including,  without  limitation,  the  right  to  grant  the  licenses  granted
hereunder.

4.2  AUTHORITY.  As of the Effective Date, each Party represents and warrants to
the  other that it (a) has the corporate power and authority and the legal right
to  enter  into  this  Agreement  and perform its obligations hereunder; (b) has
taken  all  necessary  corporate  action  on  its part required to authorize the
execution  and  delivery of the Agreement and the performance of its obligations
hereunder;  and (c) the Agreement has been duly executed and delivered on behalf
of  such  Party,  and  constitutes a legal, valid and binding obligation of such
Party  and  is  enforceable  against  it  in  accordance  with  its  terms.

4.3  NO  APPROVALS OR CONSENTS. Except as otherwise described in this Agreement,
each  Party  represents  and  warrants to the other that all necessary consents,
approvals  and  authorizations of all governmental authorities and other persons
or  entities required to be obtained by such Party in connection with entry into
this  Agreement  have  been  obtained.

<PAGE>
4.3  NO  CONFLICT.  Each  Party  represents  and  warrants to the other that the
execution  and  delivery  of  the Agreement by such Party and the performance of
such  Party's  obligations  hereunder  (a)  do  not conflict with or violate any
requirement  of  applicable  law  or  regulation or any provision of articles of
incorporation  or  bylaws  of  such  Party  in  any material way, and (b) do not
conflict  with, violate or breach or constitute a default or require any consent
under, any contractual obligation or court or administrative order by which such
Party  is  bound.

4.4  IMPLIED  WARRANTIES. LICENSOR MAKES NO REPRESENTATION OR WARRANTY AS TO THE
LICENSED  PATENTS, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY
STATUTE OR OTHERWISE, AND LICENSEE SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED OR
STATUTORY WARRANTIES. Without limiting the foregoing, Licensee acknowledges that
it  has  not  and  is  not relying upon any implied warranty of merchantability,
fitness  for  a  particular  purpose or otherwise, or upon any representation or
warranty whatsoever as to the prospects (financial, regulatory or otherwise), or
the  validity  or  likelihood  of  success,  of  the  Products.

5.  CONFIDENTIALITY.

5.1  Except  as provided elsewhere in this Agreement, Licensor and Licensee each
agree  to  maintain confidential information in confidence and not use, transfer
or  disclose  such  confidential  information to a third party without the prior
written  approval  of  the  other  Party,  except  as  is  contemplated  by this
Agreement,  or as is required to be disclosed to recover damages for a breach of
this  Agreement,  or  as  is required to comply with any order of a court or any
applicable  rule,  regulation,  or  law of any jurisdiction. In the event that a
Party is required by judicial or administrative process to disclose confidential
information  of  the  other  Party  (except  with  respect to disclosures to tax
authorities), it shall promptly notify the other Party and allow the other Party
a reasonable time to oppose such process. For disclosures to tax authorities, no
prior  notification  to  the  other  Party  shall  be  required.  The  foregoing
obligations  shall remain in force until ten (10) years following termination of
this  Agreement  by either Party, except with respect to trade secrets for which
such  obligations  shall  continue  in  perpetuity.

5.2  Both  Licensor and Licensee shall protect confidential information by using
the  same  degree  of  care,  but  not less than a reasonable degree of care, to
prevent  the unauthorized disclosure or use of confidential information, as that
Party  uses  to  protect  its  own  confidential  information  of  like  nature.

5.3 Any provision of this Agreement to the contrary notwithstanding, the parties
shall  be entitled to disclose confidential information to the extent reasonably
necessary  for the purposes of this Agreement, to their respective  consultants,
outside  contractors  and  clinical  investigators  on  the  condition that such
persons  and  entities  agree  to  be  bound  by  this Agreement with respect to
nondisclosure  and/or  non-use  of  such  information.

6.  INTELLECTUAL  PROPERTY  MANAGEMENT

6.1  PATENT  PROSECUTION  AND MAINTENANCE. Licensor shall be responsible for the
preparation,  filing,  prosecution  and  maintenance  of  the  Licensed  Patents
including  all  payment

<PAGE>
obligations and shall on an ongoing basis promptly furnish copies of all related
documents  to  Licensee  within  thirty  (30)  days  of  receipt  or deposition.

6.1.1  Licensor  shall,  subject  to  the  prior approval of Licensee (not to be
unreasonably  withheld),  select registered patent attorneys or patent agents to
provide services for preparing, filing, prosecuting and maintaining the Licensed
Patents.  Licensor  shall  directly  pay  such  attorneys  or agents and provide
Licensee  copies  of  each  invoice  associated  with  such services, as well as
documentation  that  such  invoices  have  been  paid.

6.1.2  The parties agree to cooperate in connection with the filing, prosecution
and  maintenance  of  the  Licensed  Patents  and  to  take  any and all actions
necessary to transfer the necessary documents and rights required for, and to do
such  other  things  as  are  from  time  to  time  necessary to comply with the
requirements  of  this  Section.

6.1.3  Each Party shall promptly inform the other as to all matters that come to
its  attention  that  may  affect  the  preparation,  filing,  prosecution,  or
maintenance  of  the  Licensed Patents and permit each other to provide comments
and  suggestions with respect to such activities, which comments and suggestions
shall  be  reasonably  considered  by  the  other  Party.

6.1.4  Upon  receipt  of approval to market Product in a country of a Territory,
Licensor  shall  provide  assistance to Licensee in obtaining patent extensions,
supplementary  protection certificates, and the like for the Licensed Patents to
the extent the laws of the country provide it. It is understood that Licensee is
responsible  for  promptly notifying Licensor of receipt of Regulatory Approval.
Licensee  shall  provide  Licensor  with  at least sixty (60) days prior written
notice  before  surrendering or abandoning any Licensed Patent in any country of
the  Territory.

6.1.5 Except with respect to the prosecution of the Patent Application  as filed
in  the  United  States  and  the  maintenance  of the patent issuing therefrom,
Licensor may, upon ninety (90) days written notice to Licensee,  elect to not to
file  applications  in additional jurisdictions or to surrender its rights under
any  particular  Licensed Patent in any jurisdiction and owe no payment or other
obligation  under  this  section  for  patent-related  expenses incurred in that
country  as  to  such  Licensed  Patent as of the effective date of such written
notice.  To the extent that Licensee desires to file and/or continue maintenance
and/or  prosecution  of  such  Licensed  Patents  in such jurisdictions in which
Licensor  has  elected  not  to  file and/or to surrender rights, Licensor shall
cooperate  fully  with  Licensee,  its  attorneys,  and  agents in assuming such
responsibilities  and  provide  Licensee  with  complete  copies  of any and all
documents  or  other  materials  that Licensee deems necessary to undertake such
responsibilities.

7.     INFRINGEMENT  AND  MISAPPROPRIATION.

7.1 NOTICE. Each Party shall promptly notify the other in writing of any alleged
infringement  or  misappropriation  by  third  parties of any Licensed Patent or
Licensed Technology and provide any information available to that Party relating
to  such  alleged  infringement  or  misappropriation.

7.2  ENFORCEMENT OF LICENSED PATENTS. Licensor shall have the primary right, but
not  the  obligation,  to take action in its own name to secure the cessation of
any  infringement  or

<PAGE>
misappropriation or to enter suit against the infringer. Any such action will be
at Licensor's expense, employing counsel of its own choosing. If Licensor elects
not  to  exercise  its  right  to  prosecute or take other appropriate action in
connection  with  an infringement or misappropriation of the Licensed Patents or
fails  to take any such action within sixty (60) days of first receiving of such
infringement  or  misappropriation,  Licensee  may  do  so  at  its own expense,
controlling  such  action.  In the event of any infringement or misappropriation
suit against a third party brought by either Party pursuant to this Section, the
Party  so  proceeding shall pay to the other Party all of its costs and expenses
(but  not  attorney's  fees) in connection with such action and such other Party
shall join in and reasonably cooperate with respect to such action to the extent
necessary  to  initiate  and maintain it (e.g., by providing relevant documents,
witnesses  and  testimony,  etc.).

7.3  ALLOCATION  OF DAMAGES OR OTHER MONETARY AWARDS. If Licensor brings action,
any  damages  or  other  monetary  awards recovered by Licensor shall be applied
proportionately  first  to defray the unreimbursed costs and expenses (including
reasonable attorneys' fees) incurred by either or both Parties in the action. If
any balance remains, such balance shall be the property of Licensor. If Licensor
fails  to bring action and Licensee brings action, any damages or other monetary
awards  recovered  by  Licensee  shall  be applied first to defray the costs and
expenses (including reasonable attorneys' fees) incurred in the action by either
or  both  of  the  Parties.  If  any  balance remains, such balance shall be the
property  of  Licensee.

7.4  SETTLEMENT  PROCEDURES.  In the event that a party bringing suit under this
Section  7 dispose of the matter by way of settlement, consent judgment or other
voluntary  final  disposition,  which  settlement, judgment or disposition would
alter,  derogate  or  diminish  such other Party's rights under the Agreement or
otherwise materially adversely affect such other Party, such settlement, consent
judgment  or  other voluntary final disposition shall require the consent of the
other  Party,  which  consent  shall  not  be  unreasonably withheld or delayed.

8.     TERMINATION.  Either party may terminate this Agreement by Notice, if the
other  commits  a  material  breach  of this Agreement which is not cured within
thirty days' following Notice. Any such termination shall end the license rights
granted  to  Licensee under Section 1, provided, however, that Licensee shall be
entitled  to  exhaust existing inventories of Products, including as inventories
Products  already in production.  Upon termination of this Agreement, whether by
Licensor  or  Licensee, Licensee shall cease all use of any biological materials
and shall, upon request, return or destroy (at Licensor's option) all biological
materials  under  its  control  or  in its possession within sixty (60) days and
provide  a  written  warranty  by  an  Officer  of  Licensee that the biological
materials  have  been  returned  or  destroyed.

9.     OTHER  MATTERS.
     9.1  NOTICE.  "Notice" means notice given as described here. Notice will be
     given  to  Licensor  at  16  East  34  Street New York, N.Y. 10016 , and to
     Licensee,  at NexGen Bacterium Inc Arango-Orillac Building 2nd Floor , East
     54  Street Panama. Each party can change its own Notice address, by Notice.
     All  notices  or  other  communications  required  or permitted to be given
     hereunder  shall  be in writing and shall be deemed to have been duly given
     if  delivered  by  hand, facsimile and confirmed in writing or mailed first
     class,  postage  prepaid,  by  registered  or

<PAGE>
     certified mail, return receipt requested (mailed notices shall be deemed to
     have been given three (3) days after mailing; notices sent by facsimile and
     confirmed  in  writing  shall  be  deemed  given  on  the  date  sent).

9.2  SEVERABILITY.  Each clause of this agreement is severable. If any clause is
ruled  void  or  unenforceable,  the  balance of the agreement shall nonetheless
remain  in  effect.

9.3  WAIVER;  REMEDIES. Any term or provision of this Agreement may be waived at
any  time  by  the Party entitled to the benefit thereof by a written instrument
executed  by  such  Party. No delay on the part a Party in exercising any right,
power  or  privilege  hereunder shall operate as a waiver thereof, nor shall any
waiver  on  the  part of either Party of any right, power or privilege hereunder
operate  as  a waiver of any other right, power or privilege hereunder nor shall
any  single  or  partial  exercise  of  any  right, power or privilege hereunder
preclude  any  other  or  further  exercise thereof or the exercise of any other
right,  power  or  privilege  hereunder.

9.4  ASSIGNMENT.  This  agreement  may  not  be assigned by Licensee without the
express  written  consent  of  Licensor,  which consent will not be unreasonably
withheld.

9.5  GOVERNING  LAW, JURISDICTION. This agreement is governed by the laws of the
State of New York. Any action brought between the parties may be brought only in
the  state  or  federal courts located in New York, and in no other place unless
the  parties  expressly  agree  in  writing  to  waive  this  requirement.

9.6  ATTORNEYS'  FEES. The prevailing party in any suit, action, arbitration, or
appeal  filed  or held concerning this agreement shall be entitled to reasonable
attorneys'  fees.

9.7 REPRESENTATION. This document is the result of negotiations between parties,
each  of  which  was represented or had the opportunity to be represented in the
transaction, and has had the opportunity to have had the transactional documents
reviewed  by  counsel  of  its  own  choice.

9.8  ENTIRE  AGREEMENT.  This Agreement constitutes the entire agreement between
the  Parties  with respect to the subject matter hereof and supersedes all prior
communications,  agreements  or  understandings, written or oral, of the Parties
relating  thereto.

9.9  ATTACHMENTS.  All  Exhibits  and other attachments to this Agreement are by
this  reference  incorporated  herein  and  made  a  part  of  this  Agreement.

9.10  AMENDMENT.  This  Agreement  may  be  modified  or amended only by written
agreement  of  the  Parties  hereto.

9.11 COUNTERPARTS. This Agreement may be executed in any number of counterparts,
each  of  which  shall  be  deemed  an  original but all of which together shall
constitute  a  single  instrument

LICENSOR                                            LICENSEE

<PAGE>
By:  /s/  Paul Stark                By:  /s/ Michel Marechal  Norma  uezo
-------------------------------     ------------------------------

Print:  Paul Stark                  Print:  Michel Marechal  Norma Nuezo
-------------------------------     ------------------------------

Title:  Chief Business Officer      Title:  General Attorneys
-------------------------------     ------------------------------

Date:   August 18, 2003             Date:  August 11, 2003
-------------------------------      ------------------------------

m/LICENSE  AGREEMENT

<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]